Neuroprotective effect of nicorandil in 6-OHDA induced in vitro model of parkinson's disease

Neuroprotective effect of nicorandil in 6-OHDA induced in vitro model of parkinson's disease

The purpose of this study was to examine the consequences of opening KATP channels using nicorandil in an in vitro 6-OHDA Parkinson’s disease model conducted in SH-SY5Y cells. To establish Parkinson’s disease model in vitro, 200μM 6-OHDA administered to the cells for 24h. Half an hour before the 6-OHDA administration, SH-SY5Y cells were pre-treated with nicorandil (10, 100, 500 and 1000μM). After 1 day, cell viability was determined with the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and lactate dehydrogenase (LDH) assays. Oxidative stress was assessed with superoxide dismutase (SOD), glutathione (GSH), reactive oxygen species (ROS) and malondialdehyde (MDA) analyses. We found that 6-OHDA increased LDH leakage, and cellular apoptosis in SH-SY5Y cells. 6-OHDA aggravated oxidative stress by increasing ROS and MDA and eventually promoted apoptosis by increasing mRNA expression levels of Caspase-3 in SH-SY5Y cells, while pretreatment with nicorandil attenuated these toxic effects of 6-OHDA by suppressing oxidative stress and apoptosis. Considering its neuroprotective role in addition to its effects on oxidative stress and apoptosis, nicorandil may be a useful agent in the treatment of Parkinson’s disease.

___

  • 1. Collaborators GBDPsD. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939-53.
  • 2. Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev. 2017;35:33-50.
  • 3. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.
  • 4. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem. 2001;76:1785-93.
  • 5. Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia. 2017;32:533-9.
  • 6. Teshima Y, Akao M, Baumgartner WA, et al. Nicorandil prevents oxidative stress-induced apoptosis in neurons by activating mitochondrial ATPsensitive potassium channels. Brain Res. 2003;990:45-50.
  • 7. Robin E, Simerabet M, Hassoun SM, et al. Postconditioning in focal cerebral ischemia: role of the mitochondrial ATP-dependent potassium channel. Brain Res. 2011;1375:137-46.
  • 8. Zhang F, Cui J, Lv B, et al. Nicorandil protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Int J Mol Med. 2015;36:415-23.
  • 9. Okkay U, Ferah Okkay I, Aydin IC, et al. Effects of Achillea millefolium on cisplatin induced ocular toxicity: an experimental study. Cutan Ocul Toxicol. 2021:1-7.
  • 10. Okkay U, Ferah Okkay I, Cicek B, et al. Achillea millefolium alleviates testicular damage in paclitaxel-intoxicated rats via attenuation of testicular oxido-inflammatory stress and apoptotic responses. Andrologia. 2021;53:e14028.
  • 11. Ravindran S, Swaminathan K, Ramesh A, et al. Nicorandil attenuates neuronal mitochondrial dysfunction and oxidative stress associated with murine model of vascular calcification. Acta Neurobiol Exp (Wars). 2017;77:57-67.
  • 12. Zhao Y, Yang Z, He Y, et al. The KATP channel opener, nicorandil, ameliorates brain damage by modulating synaptogenesis after ischemic stroke. PLoS One. 2021;16:e0246019.
  • 13. Zhao AP, Dong YF, Liu W, et al. Nicorandil inhibits inflammasome activation and Toll-like receptor-4 signal transduction to protect against oxygen-glucose deprivation-induced inflammation in BV-2 cells. CNS Neurosci Ther. 2014;20:147-53.
  • 14. 1Tabeshmehr P, Husnain HK, Salmannejad M, et al. Nicorandil potentiates sodium butyrate induced preconditioning of neurons and enhances their survival upon subsequent treatment with H2O2. Transl Neurodegener. 2017;6:29.
  • 15. Maneuf YP, Duty S, Hille CJ, et al. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Exp Neurol. 1996;139:12-6.
  • 16. Xu Z, Yang D, Huang X, et al. Astragaloside IV Protects 6-Hydroxydopamine- Induced SH-SY5Y Cell Model of Parkinson's Disease via Activating the JAK2/STAT3 Pathway. Front Neurosci. 2021;15:631501.
  • 17. Tungalag T, Yang DK. Sinapic Acid Protects SH-SY5Y Human Neuroblastoma Cells against 6-Hydroxydopamine-Induced Neurotoxicity. Biomedicines. 2021;9.
  • 18. Busija DW, Gaspar T, Domoki F, et al. Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. Adv Drug Deliv Rev. 2008;60:1471-7.
  • 19. Casares D, Escribá PV, Rosselló CA. Membrane lipid composition: effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Molecular Sciences. 2019;20:2167.
  • 20. Ahiskali I, Ferah Okkay I, Mammadov R, et al. Effect of taxifolin on cisplatin-associated oxidative optic nerve damage in rats. Cutan Ocul Toxicol. 2021;40:1-6.
  • 21. Kong J, Ren G, Jia N, et al. Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease. Eur Neurol. 2013;70:233-41.
  • 22. Ren J, Yuan L, Wang W, et al. Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway. Toxicol Appl Pharmacol. 2019;378:114617.
  • 23. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-94.
  • 24. Owjfard M, Bigdeli MR, Safari A, et al. Effects of nicorandil on neurobehavioral function, BBB integrity, edema and stereological parameters of the brain in the sub-acute phase of stroke in a rat model. J Biosci. 2020;45
Medicine Science-Cover
  • ISSN: 2147-0634
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2012
  • Yayıncı: Effect Publishing Agency ( EPA )
Sayıdaki Diğer Makaleler

Appendiceal neoplasms: Evaluation of 4761 appendectomy specimens

Kemal EYVAZ, Kadir BALABAN, Tuğrul ÇAKIR, Arif ASLANER, Nedim AKGÜL, Murat Kazım KAZAN, Mehmet ÖLÇÜM

Flexible approaches are required for successful production of recombinant proteins in plants

Tarlan MAMEDOV, Nilufer GÜN

Pediatric tracheotomy: Results of a single center study on 46 patients

Mehmet TAN, Tuba BAYINDIR, Emrah GÜNDÜZ, Hatice ÇELİK

Effects of different larenageal mask types on hemodynamics and airway in pediatric

Hatice SELÇUK KUŞDERCİ, mesut öterkuş

Levels of obestatin in euthyroid patients receiving levothyroxine replacement therapy

ARZU BİLEN, NURİNNİSA ÖZTÜRK, Filiz MERCANTEPE, Ramazan DAYANAN, Serpil ÇİFTEL, Enver ÇİFTEL, Habib BİLEN, İlyas ÇAPOĞLU

Regenerative effects of some antioxidants after liver resection

İsmet YILMAZ, Muhammet Burak AÇIKGÜL

Acute enteric eosinophilic myenteric ganglionitis: A challenging and uncommon case of lung adenocarcinoma

Metin ERTEM, Emel ÖZVERİ, Deniz Esin TEKCAN ŞANLI, Şafak KIZILTAŞ, Serpil YILMAZ, Ahmet Necati ŞANLI

Covid-19 related anxiety levels of emergency service personnel: A cross-sectional study from Turkey

Emine KADIOĞLU, Serhat KARAMAN, Ahmet CEYLAN, Mustafa ÇALIK, Ahmet Burak ERDEM, Ozlem ARIK, Abdurrahman YILMAZ, Hasan AYDIN, Abdil COŞKUN, Esref GENÇ, Zeynep Yildiz AKBEY, Harun YILDIRIM, Murtaza KAYA

Evaluation of the effect of obesity on fibromyalgia in premenopausal female patients

Müjgan GÜRLER, Dicle AYDOĞDU OĞUZ

Respiratory system symptoms in marble quarry and marble factory workers

Ahmet DUMANLI, Suphi AYDIN